| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | 101.13% | Barclays | $60 → $57 | Maintains | Overweight |
| 10/03/2023 | 139.94% | RBC Capital | → $68 | Reiterates | Outperform → Outperform |
| 08/03/2023 | 76.43% | Piper Sandler | $60 → $50 | Maintains | Overweight |
| 08/03/2023 | 94.07% | Truist Securities | $60 → $55 | Maintains | Buy |
| 08/03/2023 | 139.94% | RBC Capital | $70 → $68 | Maintains | Outperform |
| 08/03/2023 | 76.43% | TD Cowen | → $50 | Upgrades | Market Perform → Outperform |
| 08/03/2023 | 122.3% | HC Wainwright & Co. | $68 → $63 | Maintains | Buy |
| 08/03/2023 | 83.49% | Needham | $60 → $52 | Maintains | Buy |
| 07/13/2023 | 139.94% | HC Wainwright & Co. | $71 → $68 | Maintains | Buy |
| 05/15/2023 | 111.71% | Piper Sandler | → $60 | Maintains | Overweight |
| 05/04/2023 | 154.06% | RBC Capital | $75 → $72 | Maintains | Outperform |
| 05/04/2023 | 150.53% | HC Wainwright & Co. | → $71 | Reiterates | → Buy |
| 04/25/2023 | 118.77% | Piper Sandler | → $62 | Maintains | Overweight |
| 04/20/2023 | 111.71% | Needham | → $60 | Reiterates | → Buy |
| 03/01/2023 | 168.17% | RBC Capital | $80 → $76 | Maintains | Outperform |
| 03/01/2023 | 150.53% | HC Wainwright & Co. | $69 → $71 | Maintains | Buy |
| 02/28/2023 | 111.71% | Needham | $63 → $60 | Maintains | Buy |
| 02/10/2023 | 143.47% | HC Wainwright & Co. | $76 → $69 | Reiterates | → Buy |
| 01/31/2023 | 111.71% | Wedbush | → $60 | Assumes | → Outperform |
| 01/06/2023 | 83.49% | BMO Capital | $60 → $52 | Maintains | Market Perform |
| 01/06/2023 | 122.3% | Needham | $66 → $63 | Maintains | Buy |
| 11/07/2022 | 111.71% | BMO Capital | $66 → $60 | Maintains | Market Perform |
| 11/04/2022 | 168.17% | HC Wainwright & Co. | $83 → $76 | Maintains | Buy |
| 11/03/2022 | 161.12% | Needham | $76 → $74 | Maintains | Buy |
| 10/21/2022 | 132.89% | Jefferies | → $66 | Assumes | → Buy |
| 08/04/2022 | 168.17% | Piper Sandler | $80 → $76 | Maintains | Overweight |
| 07/21/2022 | 182.29% | Piper Sandler | $84 → $80 | Maintains | Overweight |
| 06/15/2022 | 168.17% | Needham | $84 → $76 | Maintains | Buy |
| 02/28/2022 | 231.69% | Wedbush | $97 → $94 | Maintains | Outperform |
| 02/25/2022 | 217.57% | HC Wainwright & Co. | $86 → $90 | Maintains | Buy |
| 01/19/2022 | 238.74% | Barclays | $92 → $96 | Maintains | Overweight |
| 11/05/2021 | 224.63% | Barclays | $91 → $92 | Maintains | Overweight |
| 11/04/2021 | 203.46% | HC Wainwright & Co. | $80 → $86 | Maintains | Buy |
| 10/18/2021 | 196.4% | Needham | $80 → $84 | Maintains | Buy |
| 10/12/2021 | 182.29% | HC Wainwright & Co. | $84 → $80 | Maintains | Buy |
| 10/01/2021 | 221.1% | Barclays | $95 → $91 | Maintains | Overweight |
| 08/04/2021 | 196.4% | HC Wainwright & Co. | $86 → $84 | Maintains | Buy |
| 07/26/2021 | 164.64% | JP Morgan | → $75 | Upgrades | Neutral → Overweight |
| 05/10/2021 | 147% | BMO Capital | $72 → $70 | Maintains | Market Perform |
| 05/05/2021 | 132.89% | Northland Capital Markets | $75 → $66 | Maintains | Market Perform |
| 04/09/2021 | 228.16% | Berenberg | → $93 | Initiates Coverage On | → Buy |
| 03/01/2021 | 203.46% | HC Wainwright & Co. | $70 → $86 | Maintains | Buy |
| 01/21/2021 | 164.64% | SVB Leerink | $63 → $75 | Downgrades | Outperform → Market Perform |
| 01/08/2021 | 168.17% | Needham | $67 → $76 | Maintains | Buy |
| 12/09/2020 | 136.41% | Needham | $68 → $67 | Maintains | Buy |
| 11/02/2020 | 192.87% | Wedbush | $85 → $83 | Maintains | Outperform |
| 09/21/2020 | 136.41% | Northland Capital Markets | $58 → $67 | Upgrades | Market Perform → Outperform |
| 09/09/2020 | 139.94% | Needham | $64 → $68 | Maintains | Buy |
| 07/13/2020 | 139.94% | HC Wainwright & Co. | $63 → $68 | Reiterates | → Buy |
| 07/10/2020 | 143.47% | Jefferies | $53 → $69 | Maintains | Buy |
| 07/06/2020 | 125.83% | Needham | $52 → $64 | Maintains | Buy |
| 05/27/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 05/08/2020 | 69.37% | Stifel | $49 → $48 | Maintains | Hold |
| 05/08/2020 | 58.79% | SVB Leerink | $44 → $45 | Maintains | Outperform |
| 04/30/2020 | 83.49% | Needham | $56 → $52 | Maintains | Buy |
| 04/07/2020 | 76.43% | Northland Capital Markets | → $50 | Initiates Coverage On | → Outperform |
| 03/20/2020 | 55.26% | SVB Leerink | $46 → $44 | Upgrades | Market Perform → Outperform |
| 02/24/2020 | 122.3% | HC Wainwright & Co. | $60 → $63 | Maintains | Buy |
| 01/24/2020 | 111.71% | SunTrust Robinson Humphrey | → $60 | Initiates Coverage On | → Buy |
| 11/06/2019 | 97.6% | BTIG | → $56 | Initiates Coverage On | → Buy |
| 08/09/2019 | 51.73% | BMO Capital | $46 → $43 | Maintains | Market Perform |
| 06/11/2019 | 83.49% | Barclays | → $52 | Initiates Coverage On | → Overweight |
| 05/06/2019 | 34.09% | Mizuho | $29 → $38 | Upgrades | Underperform → Neutral |
| 02/01/2019 | — | Mizuho | Downgrades | Neutral → Underperform | |
| 11/02/2018 | 76.43% | JP Morgan | $45 → $50 | Maintains | Neutral |
| 11/02/2018 | 65.84% | BMO Capital | $40 → $47 | Maintains | Market Perform |
| 11/02/2018 | 122.3% | JMP Securities | $56 → $63 | Maintains | Market Outperform |
What is the target price for Pacira BioSciences (PCRX)?
The latest price target for Pacira BioSciences (NASDAQ: PCRX) was reported by Barclays on October 23, 2023. The analyst firm set a price target for $57.00 expecting PCRX to rise to within 12 months (a possible 101.13% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacira BioSciences (PCRX)?
The latest analyst rating for Pacira BioSciences (NASDAQ: PCRX) was provided by Barclays, and Pacira BioSciences maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Pacira BioSciences (PCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
Is the Analyst Rating Pacira BioSciences (PCRX) correct?
While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a maintained with a price target of $60.00 to $57.00. The current price Pacira BioSciences (PCRX) is trading at is $28.34, which is out of the analyst's predicted range.